TriSalus Life Sciences (TLSI) logo

TriSalus Life Sciences (TLSI) stock

Cancer drug devices , market cap $134M

$2.32
+6.67%

Why TLSI fell on Nov 10

Down 12% on Nov 10, and still 28% under its Nov 9 close.

Sources: Price history, Nov 10, 2026; SEC filing, Nov 10, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time TLSI moves

Free account, no card. An optional alert when TLSI moves or its score changes.Pro, $1 for a first month. An optional alert when TLSI moves or its score changes.Pro, 7 days free with a card. An optional alert when TLSI moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on TLSI →1 more reason why TLSI fell on Nov 10, from its filings, with the timeline and its peers, for Pro members.
Quality Score
-5
Poor
In its industry
#80of 86
Checks firing
3of 14
Trending down
From 52-week high
-70.8%
under its best in a year
See TLSI's 14 chart checksSee TLSI's 14 chart checksSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on TLSI

Key facts on TLSI
Holding it back35.8% more shares than a year ago
Latest filing10-Q, Nov 10 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

What's next

Tue Dec 1: Piper Sandler 38th Annual…Investor conference · date confirmed.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

TLSI catalysts

Coming up

After its last 4 reports it closed -11.0% on average, higher 1 of 4 times.

How TLSI ranks in Medical Devices

TLSI is #80 of 86 by Quality Score.

How TLSI ranks in Medical Devices
RankStockQuality Score
80TriSalus Life Sciences (TLSI) logoTLSITriSalus Life Sciences-5

More in Medical Devices

When does TLSI report earnings, and what happens after?

Expected to report Thu Mar 4, before the open (in 103 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What TLSI reported on Nov 10, 2026

The quarter

The figures are not read from the release yet.

“The increase in revenue was primarily due to an increase in TriNav units sold.”

The filing on EDGAR

Where the sales came from

TLSI's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
MeasureFigure
Full year 2026
Revenue$46M to $48Mcut

Figures as filed (SEC filing, Nov 10)

In the company's words

  • “The year-over-year increase in gross margin was primarily due to a reduction in cost per TriNav unit.”

From its results filing (SEC filing · Nov 10)

The numbers

Market value
$134M
today
Sales
$46.4M
up 15.4% on the year
Free cash flow
-$24.7M
last 12 months

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on TLSI: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-41.5%+15.2%-11.5%
May 12Aug 6Nov 10
ReportedGapReaction5
days
Nov 10, 2026Before open-20.5%-11.5%-29.5%
Aug 6, 2026After close+1.4%+15.2%+15.6%
May 12, 2026After close-21.1%-41.5%-30.9%

TLSI closed higher after 1 of its last 4 reports.

All 4 reports, and TLSI's Quality Score going into each

TLSI sales and profit by year

Sales and profit by year

Sales grew every year from 2022 to 2025, to $45.2M. It lost money in each of the four years.

TLSI has 3 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on TLSI, and all 14 on every stock.Get in free →See the top 3 →Start Pro

TLSI RSI on Nov 20: 32.4, below its 50-day and 200-day averages

Not scored

RSI 32.4, MACD below signal, below both averages. Not scored.

The deep dive on TLSI

13 more findings on TLSI, each with its source, for Pro members.

TLSI share count over time

Shares: 35.8% more than a year ago (to Sep 30).

Shares of TLSI outstanding, as filed
Shares
outstanding
As
of
61.7MNov 6, 2026
61.6MAug 4, 2026
61.4MMay 8, 2026
61.3MMar 2, 2026
Offerings, shelves, and splits of TLSI, from its filings
From its
filings
Filed
Raised $40M in a sale of shares, about 30% of its market valueFeb 26, 2026

TLSI insider trades

3 insiders bought $294K across 4 filings, and 3 insiders sold $5K across 4 filings, in the last 6 months. The newest:

BuyMary T. Szela$89KCEO and Presidentat $2.59 on Nov 18, filed Nov 19

All 8 insider filings on TLSI from the last six months, for Pro members.

All TLSI insider trades

TLSI's officers and directors

Officers and directors with a Form 4 in the last 12 months.

5 more officers and directors file at TLSI.

See insider trades by person

Which ETFs hold TLSI?

In ETFs: TLSI is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About TriSalus Life Sciences

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

102 employeesWestminster, COtrisaluslifesci.com

What TriSalus Life Sciences says it competes with

“Our industry is highly competitive and subject to rapid and significant technological change as research provides a deeper understanding of the pathology of diseases and new technologies and treatments are developed.”

From its annual report, SEC filing · Mar 5, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on TLSI and every other stock.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn TLSI's score around: 9 things
  • 4 more filings explained, a plain line each
  • 5 more things pulling TLSI's score down
BreakawayNov 19Mary T. Szela bought TLSI$89K at $2.59, filed Nov 19

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: TLSI's Quality Score is -5 (Poor), #80 of 86 in Medical Devices. Insiders bought $294K and sold $5K in the last 6 months (Form 4).

What does TLSI's Quality Score say?

TLSI scores -5 today, which Breakaway calls Poor. It is #80 of 86 in Medical Devices by Quality Score, with 3 of 14 chart checks firing. Down 12% on Nov 10, and still 28% under its Nov 9 close. Shares: 35.8% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is TLSI's Quality Score?

TLSI scores -5 today, which Breakaway calls Poor (below zero). That is #80 of 86 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TLSI's -5.

Are insiders buying TLSI?

3 insiders bought $294K across 4 filings, and 3 insiders sold $5K across 4 filings, in the last 6 months. The newest is Mary T. Szela, CEO and President, who bought $89K on Nov 18. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.